Skip to content
Peptigraph home

BPC-157 for dogs: What the Evidence Shows

What is known about bpc-157 for dogs: veterinary studies, approval status for animals, and the questions to ask your vet.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated

At a glance

Animal
Dogs
Evidence in dogs
2 studies in dogs
Status in people
PCAC voted 8–6 for 503A (Jul 2026)
Evidence

What is known in dogs

Outcomes from published studies that included dogs, quoted from each abstract. Studies only in people or rodents are not evidence for dogs and are left out.

BPC-157 for dogs: outcomes in studies of dogs
OutcomeResultStudy typeSource
Elimination half-lifeElimination half-life of BPC157 was under 30 minutes in rats and beagle dogs, with linear pharmacokinetics.Animal · rat, beagle dog (not a human result)Frontiers in pharmacology 2022, PMID 36588717
Bioavailability after IM injectionIntramuscular bioavailability was approximately 14%-19% in rats and 45%-51% in beagle dogs.Animal · rat, beagle dog (not a human result)Frontiers in pharmacology 2022, PMID 36588717
Overall preclinical tolerabilityWell tolerated with no serious toxicity in the four animal species tested.Animal · mouse, rat, rabbit, dog (not a human result)Regulatory toxicology and pharmacology 2020, PMID 32334036
Do not give dogs a product meant for people, or one sold “for research use only”. Doses, safety and side effects differ by species. Ask your vet first.
Your vet

Questions to ask your vet

  • Is there an approved veterinary product for this condition?
  • Has this been studied in my pet's species, and at what dose?
  • What side effects or interactions should I watch for?
  • How will we know whether it is working, and when do we stop?

The only dog data are pharmacokinetics in laboratory beagles

A pharmacokinetic paper dosed rats and beagle dogs with BPC-157 intravenously and intramuscularly. The authors describe it as groundwork for future clinical applications.[1]

Intramuscular bioavailability was about 45-51% in the beagles and 14-19% in the rats.[1]

The radiolabelled part of the same study found urine and bile were the main routes of excretion.[1]

What the cached sources do not contain

The authors call it the first analysis of BPC-157 pharmacokinetics and say it should help translation in the clinic.[1]

Drugs@FDA, which covers human drug products, returns no match for BPC-157. No FDA veterinary source for it is cached here.[3]

Common questions

Is BPC-157 safe for dogs?

No dog safety study of use in pets is cached; the dog work measured how the peptide moves through the body.[1]

Is BPC-157 approved for dogs?

No approval was found. Drugs@FDA returns no match for the substance.[3]

How long does BPC-157 last in a dog?

In the beagle and rat pharmacokinetic study, the elimination half-life was under 30 minutes after intravenous or intramuscular dosing.[1]

Sources

  1. 1Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  2. 2Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds.Regulatory toxicology and pharmacology : RTP · 2020PMID 32334036Accessed 11 Oct 2026
  3. 3Drugs@FDA (openFDA) search: active ingredient "BPC-157"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.